From all this, we can conclude that DART-CLQ was instrumental in identifying a specific AKT gene module (derived from the METABRIC discovery set), which can simultaneously predict tamoxifen resistance in ER+ breast cancer patients and sensitivity to PI3K/AKT/mTOR signaling inhibitors. This evidence concerns the gene PIK3CG and breast cancer.